New joint European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension.

Introduction and purpose In preparing these guidelines the Committee established by the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) has aimed at offering the best available and most balanced information to all those involved in the management of arterial hypertension. The Committee is aware that it is easier to prepare guidelines on a medical condition in general than to deal with the individual patients with that condition requiring medical advice and intervention. Because of this awareness, the Committee has tried to avoid giving rigid rules that would constrain judgement on the management of individual patients differing in their personal, medical and cultural characteristics.

[1]  I. Bralić Primary, secondary and tertiary prevention of obesity , 2009 .

[2]  C. Mogensen,et al.  Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes * , 2003, Journal of internal medicine.

[3]  J. Staessen,et al.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003 , 2003, Journal of hypertension.

[4]  S. Tonstad,et al.  Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. , 2003, European heart journal.

[5]  Yutaka Imai,et al.  European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement , 2003, Journal of hypertension.

[6]  A. Zanchetti,et al.  Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? , 2003, Journal of hypertension.

[7]  S. Lewington Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[8]  Bryan Williams,et al.  Treating hypertension: it is not how you start but where you end that matters. , 2003, Journal of hypertension.

[9]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[10]  N. Kaplan The meaning of ALLHAT , 2003, Journal of hypertension.

[11]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[12]  P. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[13]  C. Ballantyne Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) , 2003 .

[14]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[15]  G. Mancia,et al.  New year, new challenges. , 2003, Journal of hypertension.

[16]  Deeb N Salem,et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.

[17]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[18]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[19]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[20]  Majid Ezzati,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[21]  N. Wong,et al.  Cardiovascular risk evaluation: an inexact science , 2002, Journal of hypertension.

[22]  L. Ramsay,et al.  Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods , 2002, Journal of hypertension.

[23]  A. Zanchetti,et al.  Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? , 2002, Journal of hypertension.

[24]  Michael F O'Rourke,et al.  From theory into practice: arterial haemodynamics in clinical hypertension. , 2002, Journal of hypertension.

[25]  G. Mancia,et al.  Arterial distensibility in humans. Modulating mechanisms, alterations in diseases and effects of treatment. , 2002, Journal of hypertension.

[26]  Hans L Hillege,et al.  Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population , 2002, Circulation.

[27]  M. Nieminen,et al.  Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. , 2002, JAMA.

[28]  L. Nieman Diagnostic Tests for Cushing's Syndrome , 2002, Annals of the New York Academy of Sciences.

[29]  M. Nieminen,et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study , 2002, Journal of hypertension.

[30]  S. Taddei,et al.  Endothelial dysfunction in essential hypertension: clinical implications. , 2002, Journal of hypertension.

[31]  A. Zanchetti,et al.  Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy , 2002, Journal of hypertension.

[32]  G. Mancia,et al.  Systolic and diastolic blood pressure control in antihypertensive drug trials. , 2002, Journal of hypertension.

[33]  G. Reaven Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease , 2002, Circulation.

[34]  M. Nieminen,et al.  Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study , 2002, Journal of hypertension.

[35]  G. Mancia,et al.  Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey , 2002, Journal of hypertension.

[36]  C. Tsalamandris,et al.  Albumin to creatinine ratio: a screening test with limitations. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  C. Reid,et al.  `Reverse white-coat hypertension’ in older hypertensives , 2002, Journal of hypertension.

[38]  Steven Snapinn,et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol , 2002, The Lancet.

[39]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[40]  P. Mehler,et al.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. , 2002, Kidney international.

[41]  B. Williams,et al.  Microalbuminuria in essential hypertension: redefining the threshold. , 2002, Journal of hypertension.

[42]  J. Blacher,et al.  Central Pulse Pressure and Mortality in End-Stage Renal Disease , 2002, Hypertension.

[43]  A. Simon,et al.  Intima–media thickness: a new tool for diagnosis and treatment of cardiovascular risk , 2002, Journal of hypertension.

[44]  C. Mulrow,et al.  Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[45]  J. Staessen,et al.  Results of intervention trials of antihypertensive treatment versus placebo, no or lesser treatment , 2002 .

[46]  J. Kirkpatrick Albuminuria and Risk of Cardiovascular Events , Death , and Heart Failure in Diabetic and Nondiabetic Individuals , 2002 .

[47]  J. V. van Engelshoven,et al.  Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis , 2002 .

[48]  D. Levy,et al.  Impact of high-normal blood pressure on the risk of cardiovascular disease. , 2002, The New England journal of medicine.

[49]  J F Potter,et al.  Twenty-four hour systolic blood pressure predicts long-term mortality following acute stroke , 2001, Journal of hypertension.

[50]  L. Ruilope,et al.  Renal function: the Cinderella of cardiovascular risk profile. , 2001, Journal of the American College of Cardiology.

[51]  F. Magrini,et al.  High prevalence of cardiac and extracardiac target organ damage in refractory hypertension , 2001, Journal of hypertension.

[52]  A. Zanchetti,et al.  Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study , 2001, Journal of hypertension.

[53]  G Parati,et al.  Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) , 2001, Journal of hypertension.

[54]  SalimYusuf,et al.  Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril , 2001 .

[55]  A. Zanchetti,et al.  An Italian chart for cardiovascular risk prediction. Its scientific basis. , 2001, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[56]  M. O'Rourke,et al.  Prospective Evaluation of a Method for Estimating Ascending Aortic Pressure From the Radial Artery Pressure Waveform , 2001, Hypertension.

[57]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[58]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[59]  MicheleBombelli,et al.  Alterations of Cardiac Structure in Patients With Isolated Office, Ambulatory, or Home Hypertension , 2001 .

[60]  F. Magrini,et al.  Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examination? , 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

[61]  S. Kjeldsen,et al.  Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men , 2001, Journal of hypertension.

[62]  A. Tislér,et al.  Tele-monitoring of home blood pressure. , 2001, Blood pressure monitoring.

[63]  François Gueyffier,et al.  A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials , 2001, BMJ : British Medical Journal.

[64]  A. Simon,et al.  Differential Effects of Nifedipine and Co-Amilozide on the Progression of Early Carotid Wall Changes , 2001, Circulation.

[65]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[66]  C. Held,et al.  Regression of left ventricular hypertrophy in human hypertension with irbesartan , 2001, Journal of hypertension.

[67]  R. Fagard Exercise characteristics and the blood pressure response to dynamic physical training. , 2001, Medicine and science in sports and exercise.

[68]  A. Zanchetti,et al.  Impact of the Gubbio population study on community control of blood pressure and hypertension , 2001, Journal of hypertension.

[69]  G. Parati,et al.  Blood Pressure Variability: Mechanisms and Clinical Significance , 1990, Journal of Cardiovascular Pharmacology.

[70]  J. Ménard,et al.  Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study , 2001, Journal of hypertension.

[71]  J. Gardin,et al.  Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study. , 2001, Journal of the American College of Cardiology.

[72]  Michael Peel,et al.  Blood pressure measuring devices: recommendations of the European Society of Hypertension , 2001, BMJ : British Medical Journal.

[73]  P. Ghahramani,et al.  Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials , 2001, Heart.

[74]  S. Yusuf,et al.  Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) , 2001, Circulation.

[75]  G. Mancia,et al.  Midwall Mechanics Are Improved After Regression of Hypertensive Left Ventricular Hypertrophy and Normalization of Chamber Geometry , 2001, Circulation.

[76]  S J Riederer,et al.  High-spatial-resolution contrast-enhanced MR angiography of the renal arteries: a prospective comparison with digital subtraction angiography. , 2001, Radiology.

[77]  A. Zanchetti,et al.  Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.

[78]  Emanuela Falaschetti,et al.  Association Between Smoking and Blood Pressure: Evidence From the Health Survey for England , 2001, Hypertension.

[79]  G. Bray,et al.  Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .

[80]  O. Melander Genetic Factors in Hypertension – What is Known and What Does It Mean? , 2001, Blood pressure.

[81]  T. Hedner,et al.  Stroke is More Common than Myocardial Infarction in Hypertension: Analysis based on 11 Major Randomized Intervention Trials , 2001, Blood pressure.

[82]  H. Crijns,et al.  Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial , 1999, Journal of hypertension.

[83]  R. Gordon Diagnostic investigations in primary aldosteronism , 2001 .

[84]  E. Eleuteri [Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[85]  C. Schmid,et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. , 2001, Annals of internal medicine.

[86]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[87]  D. Henderson-smart,et al.  Antiplatelet agents for preventing and treating pre-eclampsia. , 2007, The Cochrane database of systematic reviews.

[88]  P. Choyke,et al.  Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. , 2000, The Journal of clinical endocrinology and metabolism.

[89]  G Parati,et al.  Ambulatory Blood Pressure Monitoring and Organ Damage , 2000, Hypertension.

[90]  A. Rocchini Obesity hypertension, salt sensitivity and insulin resistance. , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[91]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[92]  John S. Scott,et al.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.

[93]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[94]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[95]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[96]  R. Schrier,et al.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.

[97]  M. Schroll,et al.  Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. , 2000, Hypertension.

[98]  R. Jackson,et al.  Updated New Zealand cardiovascular disease risk-benefit prediction guide , 2000, BMJ : British Medical Journal.

[99]  Karla Kerlikowske,et al.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.

[100]  P E Puddu,et al.  Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. , 2000, European heart journal.

[101]  E. Vartiainen,et al.  Cardiovascular risk factor changes in Finland, 1972-1997. , 2000, International journal of epidemiology.

[102]  M. Swiet Maternal blood pressure and birthweight , 2000, The Lancet.

[103]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[104]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .

[105]  D. Levy,et al.  Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. , 1999, Kidney international.

[106]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[107]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[108]  W. Cushman,et al.  The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.

[109]  Gianfranco Parati,et al.  Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. , 1999 .

[110]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[111]  D. Levy,et al.  Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. , 1999, Circulation.

[112]  L. Magee,et al.  Fortnightly review: management of hypertension in pregnancy. , 1999, BMJ.

[113]  R. Pini,et al.  Cardiac and Arterial Target Organ Damage in Adults with Elevated Ambulatory and Normal Office Blood Pressure , 1999, Annals of Internal Medicine.

[114]  G. Eknoyan,et al.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[115]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[116]  Karla Kerlikowske,et al.  Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials , 1999, The Lancet.

[117]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[118]  Z. Pausova,et al.  Gene-environment interactions in hypertension , 1999, Current hypertension reports.

[119]  I. U. Haq,et al.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.

[120]  M. Moser A critique of the world health organization-international society of hypertension guidelines for the management of hypertension , 1999 .

[121]  J. Chalmers Implementation of guidelines for management of hypertension. , 1999, Clinical and experimental hypertension.

[122]  F. Luft,et al.  Molecular genetics of human hypertension. , 1998, Current opinion in cardiology.

[123]  J A Staessen,et al.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension , 1998, Journal of hypertension.

[124]  A. Zanchetti,et al.  The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness , 1998, Journal of hypertension.

[125]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[126]  T. Mori,et al.  Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. , 1998, Hypertension.

[127]  R. Bigazzi,et al.  Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension , 1998, Journal of hypertension.

[128]  A. Döring,et al.  Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. , 1998, European heart journal.

[129]  K Nagai,et al.  Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. , 1998, Hypertension.

[130]  Shigeru Hisamichi,et al.  Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population‐based observation in Ohasama, Japan , 1998, Journal of hypertension.

[131]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[132]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[133]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[134]  C. Furberg,et al.  HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. , 1998, Atherosclerosis.

[135]  G. Parati,et al.  Difference between clinic and daytime blood pressure is not a measure of the white coat effect. , 1998, Hypertension.

[136]  P. Whelton,et al.  Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. , 1998, JAMA.

[137]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[138]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[139]  R. Schmieder,et al.  Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[140]  L. Hansson,et al.  Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. , 1998, Hypertension.

[141]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[142]  G. Reboldi,et al.  Prognostic significance of serial changes in left ventricular mass in essential hypertension. , 1998, Circulation.

[143]  J. Staessen,et al.  Should exercise blood pressure be measured in clinical practice? , 1998, Journal of hypertension.

[144]  A. Ganguly Primary aldosteronism. , 1998, The New England journal of medicine.

[145]  P. Thürmann,et al.  Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. , 1998, Circulation.

[146]  A. Amos,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[147]  L Guize,et al.  Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. , 1997, Hypertension.

[148]  T. Ohkubo,et al.  Relation between nocturnal decline in blood pressure and mortality. The Ohasama Study. , 1997, American journal of hypertension.

[149]  Ralph B D'Agostino,et al.  Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study , 1997, Diabetes.

[150]  A. Zanchetti The hypertensive patient with multiple risk factors: is treatment really so difficult? , 1997, American journal of hypertension.

[151]  M. Woodward,et al.  Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish heart health study: cohort study , 1997, BMJ.

[152]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[153]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[154]  H. Gerstein,et al.  The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. , 1997, Archives of internal medicine.

[155]  Y. Imai,et al.  Reproducibility of home blood pressure measurements over a 1-year period. , 1997, American journal of hypertension.

[156]  F. Magrini,et al.  Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. , 1997, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[157]  G. Jennings Exercise and blood pressure: Walk, run or swim? , 1997, Journal of hypertension.

[158]  R. Kronmal,et al.  Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. , 1997, Stroke.

[159]  A. Zanchetti Antihypertensive therapy: how to evaluate the benefits. , 1997, The American journal of cardiology.

[160]  J. Cutler,et al.  Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men , 1997, Annals of Internal Medicine.

[161]  I. Puddey,et al.  Alcohol, hypertension and the cardiovascular system: a critical appraisal , 1997, Addiction biology.

[162]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[163]  J. Tuomilehto,et al.  Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid? , 1997, Journal of Human Hypertension.

[164]  S. Haffner The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. , 1997, Journal of diabetes and its complications.

[165]  G Mancia,et al.  Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. , 1997, Circulation.

[166]  R H Fagard,et al.  Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. , 1997, Hypertension.

[167]  H. Drexler,et al.  Endothelial dysfunction: clinical implications. , 1997, Progress in cardiovascular diseases.

[168]  K. Zarnke,et al.  A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. , 1997, American journal of hypertension.

[169]  M. Law Epidemiologic evidence on salt and blood pressure. , 1997, American journal of hypertension.

[170]  J F Toole,et al.  Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. , 1996, Stroke.

[171]  M. Laakso,et al.  Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. , 1996, Stroke.

[172]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[173]  P. Schollmeyer,et al.  Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning. , 1996, Kidney international.

[174]  M. Rocco,et al.  Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. , 1996, JAMA.

[175]  E. Grossman,et al.  Diabetic and Hypertensive Heart Disease , 1996, Annals of Internal Medicine.

[176]  J. Staessen,et al.  Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. , 1996, Hypertension.

[177]  G. Mancia,et al.  Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. , 1996, Journal of hypertension.

[178]  S. Fo,et al.  Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. , 1996 .

[179]  S. Wannamethee,et al.  Patterns of alcohol intake and risk of stroke in middle-aged British men. , 1996, Stroke.

[180]  T. Ohkubo,et al.  Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, northern Japan. , 1996, Blood pressure monitoring.

[181]  B. Lernfelt,et al.  15-year longitudinal study of blood pressure and dementia , 1996, The Lancet.

[182]  P. Hamet,et al.  Shanghai trial of nifedipine in the elderly (STONE). , 1996, Journal of hypertension.

[183]  S. Kjeldsen,et al.  Exercise blood pressure predicts mortality from myocardial infarction. , 1996, Hypertension.

[184]  B. Krämer,et al.  Diagnostic strategies in renovascular hypertension. , 1996, Clinical nephrology.

[185]  J. Laragh,et al.  Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. , 1996, Circulation.

[186]  M. Kawi Hypertension control. Report of a WHO Expert Committee. , 1996, World Health Organization technical report series.

[187]  G. Mancia,et al.  Ambulatory blood pressure normality: results from the PAMELA study , 1995, Journal of hypertension.

[188]  A D Oxman,et al.  No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[189]  J. Cutler,et al.  Blood Pressure and Mortality Among Men With Prior Myocardial Infarction , 1995 .

[190]  I. Puddey,et al.  Exercise lowers blood pressure--sometimes? Or did Pheidippides have hypertension? , 1995, Journal of hypertension.

[191]  D. Rizzoni,et al.  Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment , 1995, Journal of hypertension.

[192]  P. Poole‐Wilson,et al.  [Prevention of coronary disease in clinical practice. Recommendations of the Task-Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension]. , 1995, Annales de cardiologie et d'angeiologie.

[193]  P Whelton,et al.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. , 1995, Hypertension.

[194]  I. Hjermann,et al.  Effect of dietary counselling on blood pressure and arterial plasma catecholamines in primary hypertension. , 1995, American journal of hypertension.

[195]  S. Yusuf,et al.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.

[196]  G. Colditz,et al.  Weight Gain as a Risk Factor for Clinical Diabetes Mellitus in Women , 1995, Annals of Internal Medicine.

[197]  D. Orth Cushing's syndrome. , 1995, The New England journal of medicine.

[198]  G. Parati,et al.  Lack of placebo effect on ambulatory blood pressure. , 1995, American journal of hypertension.

[199]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[200]  J. Laragh,et al.  Diagnosis and Treatment of Primary Hyperaldosteronism , 1994, Annals of Internal Medicine.

[201]  H. Parving,et al.  Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V , 1994, Diabetes Care.

[202]  R Doll,et al.  Mortality in relation to smoking: 40 years' observations on male British doctors , 1994, BMJ.

[203]  D. Levy,et al.  Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. , 1994, Circulation.

[204]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[205]  E. Bravo,et al.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. , 1994, Endocrine reviews.

[206]  G. Parati,et al.  Increase in blood pressure reproducibility by repeated semi‐automatic blood pressure measurements in the clinic environment , 1994, Journal of hypertension.

[207]  M. Stowasser,et al.  HIGH INCIDENCE OF PRIMARY ALDOSTERONISM IN 199 PATIENTS REFERRED WITH HYPERTENSION , 1994, Clinical and experimental pharmacology & physiology.

[208]  C. Reid,et al.  Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects , 1994, Journal of hypertension.

[209]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[210]  R. Collins,et al.  Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. , 1994, British medical bulletin.

[211]  J. Dillon The quantitative relationship between treated blood pressure and progression of diabetic renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[212]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[213]  L. Ruilope,et al.  Clinical relevance of proteinuria and microalbuminuria. , 1993, Current opinion in nephrology and hypertension.

[214]  G Mancia,et al.  Prognostic value of 24-hour blood pressure variability , 1993, Journal of hypertension.

[215]  W. G. Walker Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[216]  J. Salonen,et al.  Ultrasound B-mode imaging in observational studies of atherosclerotic progression. , 1993, Circulation.

[217]  K. Arakawa Antihypertensive mechanism of exercise. , 1993, Journal of hypertension.

[218]  K Rodahl,et al.  Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men. , 1993, The New England journal of medicine.

[219]  J. Staessen,et al.  A meta-analysis of outcome trials in elderly hypertensives. , 1992, Journal of hypertension.

[220]  R. Vandongen,et al.  Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. , 1992, Hypertension.

[221]  M. Schroll,et al.  The Glostrup Population Studies, 1964-1992. , 1992, Danish medical bulletin.

[222]  R. J. Sjoberg,et al.  The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. , 1992, Archives of internal medicine.

[223]  J. Sowers,et al.  Diabetes mellitus and hypertension. , 1992, Hypertension.

[224]  J. Staessen,et al.  Mean and range of the ambulatory pressure in normotensive subjects. , 1992, Chinese medical journal.

[225]  P. Sleight,et al.  The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension , 1992, Journal of hypertension.

[226]  H. Köhler,et al.  Acanthocyturia--a characteristic marker for glomerular bleeding. , 1991, Kidney international.

[227]  J. Stamler,et al.  Epidemiologic findings on body mass and blood pressure in adults. , 1991, Annals of epidemiology.

[228]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[229]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[230]  Paul M. Vanhoutte,et al.  The Endothelium: Modulator of Cardiovascular Function , 1990 .

[231]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[232]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[233]  G. Schillaci,et al.  Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. , 1990, Circulation.

[234]  S. Sans,et al.  Recruitment methods and differences in early, late and non-respondents in the first MONICA-Catalonia population survey. , 1990, Revue d'epidemiologie et de sante publique.

[235]  Ralph B. D'Agostino,et al.  Blood Pressure as a Risk Factor for Cardiovascular Disease The Framingham Study—30 Years of Follow‐up , 1989, Hypertension.

[236]  D. Simonson Etiology and Prevalence of Hypertension in Diabetic Patients , 1988, Diabetes Care.

[237]  T. Pickering,et al.  Do laboratory tests of blood pressure reactivity predict blood pressure changes during everyday life? , 1988, American journal of hypertension.

[238]  P. Wilson,et al.  Incidence of Diabetic Retinopathy and Relationship to Baseline Plasma Glucose and Blood Pressure , 1988, Diabetes Care.

[239]  J. Laragh,et al.  How common is white coat hypertension? , 1988, JAMA.

[240]  R. Vandongen,et al.  REGULAR ALCOHOL USE RAISES BLOOD PRESSURE IN TREATED HYPERTENSIVE SUBJECTS A Randomised Controlled Trial , 1987, The Lancet.

[241]  G Parati,et al.  Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.

[242]  R. Vandongen,et al.  Vegetarian diet in mild hypertension: a randomised controlled trial. , 1986, British medical journal.

[243]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[244]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[245]  G. Parati,et al.  Lack of alerting reactions to intermittent cuff inflations during noninvasive blood pressure monitoring. , 1985, Hypertension.

[246]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[247]  S. M. Collins,et al.  Ultrasonic backscatter and collagen in normal ventricular myocardium. , 1984, Circulation.

[248]  [Drug management]. , 1984, Pielegniarka i polozna.

[249]  C. Mogensen Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy , 1982, British medical journal.

[250]  N. Reichek,et al.  Left Ventricular Hypertrophy: Relationship of Anatomic, Echocardiographic and Electrocardiographic Findings , 1981, Circulation.

[251]  F. Messerli,et al.  Serum uric acid in essential hypertension: an indicator of renal vascular involvement. , 1980, Annals of internal medicine.

[252]  M. New,et al.  A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. , 1979, The Journal of clinical endocrinology and metabolism.

[253]  N. M. Keith,et al.  Some Different Types Of Essential Hypertension: Their Course And Prognosis , 1939, The American journal of the medical sciences.

[254]  D. Sutherland,et al.  Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. , 1966, Canadian Medical Association journal.

[255]  K. Thurau RENAL HEMODYNAMICS. , 1964, The American journal of medicine.

[256]  G. Perera Hypertensive vascular disease; description and natural history. , 1955, Journal of chronic diseases.